top of page
Insights & News


4 TIPS TO GET DIFFICULT BIOTECH PATENTS TO ISSUE
Struggling to get tough biotech patents allowed? A reactive, traditional "strategy" often fails. Try these 4 proactive, effective...
Jul 9


4 TIPS TO GET DIFFICULT BIOTECH PATENTS TO ISSUE IN THE U.S.
(Check out the short version of this post, if you don't want all the details in this patent professional version.) Introduction: It can...
Jul 8


KEEP YOUR ANNUAL IP SPEND WITHIN BUDGET WITH OUR PRIORITIZATION MATRIX TOOL (Full Version)
SUMMARY  In this post we present a prioritization matrix tool that enables your IP team to dedicate an appropriate amount of resources...
Jun 30


Assuring Your Patent And R&D Teams Are Well Connected
Biotech products and processes evolve over time. This can cause a misalignment between your issued/pending patent claims, and your...
May 7


Having Trouble Getting a Biotech Patent to Issue? Expert Declarations Can Clear the Way.
Biotech innovation is regularly faced with a thicket of prior art that applicants must navigate during patent prosecution. Examiners at...
Apr 20


Double Helix Law Turns 10!
This week, we’re celebrating a decade of helping life sciences innovators protect their groundbreaking IP. We are grateful for every...
Apr 3


Protect Clinical Updates Before They're Disclosed
SUMMARY: Biologic candidates evolve during clinical trials - so should your patents. Updated filings before public trial disclosures...
Mar 31


Is Your Biotech Patent Spend Too High?
Too many biotech companies treat IP like a checkbox. Smart ones prune ruthlessly—and build value, not just volume: Prune entire families...
Mar 28


Is Your Patent Team Doing a Good Job in Building Your Patent Portfolio?
INTRODUCTION Executives usually ask these quantitative but high-level questions: How much money did we spend on patent work this year?...
Mar 13


IP Diligence Checklist: Assure Your Company’s IP is in Order Before Reaching Out to Potential Investors or Acquirers
As a biotech company, much of your value is in (pre-revenue) and/or protected by (post-revenue) your intellectual property. As you...
Feb 20


Key Considerations for Drafting Working Examples in Biotech Patent Applications
Working examples are an important part of a biotech patent application, especially because this is considered an unpredictable art in...
Feb 7


USPTO Patent Fee Increases Set for Jan 19, 2025, Probably
SUMMARY Costs for prosecuting patents at the USPTO are set to increase on 1/19/25 Across-the-board 7.5% increase in fees Some targeted...
Dec 20, 2024


Surprising Results: A "Key Ingredient" For Your Patent Portfolio Build
Like many technology areas, the vast majority of, if not all, biotech/biopharma inventions build on prior art teachings. Thus, a major...
Nov 7, 2024


USPTO's Section 101 Subject Matter Eligibility - Biotech Examples & Analyses
The USPTO has provided 49 examples* to help understand the application of Section 101 (35 U.S.C. 101), subject matter eligibility, in...
Oct 25, 2024


Common Misconceptions About Patent Rights
Common misconceptions about patent rights: In my decades of counseling life sciences companies, I have found that many inventors and...
Oct 16, 2024


FTO - When Is It Time?
When should we assure we have FTO for our private biotech company? Summary: FTO for a private biotech company is typically a multi-stage...
Oct 3, 2024


101 Rejection Trends Over the Past Years
101 rejections at the USPTO plummeted in computational biology in 2023!    We analyzed office actions since 2008 related to...
Sep 18, 2024


Extended Patent Family Buildout - 3 Key Zones of Opportunity
INTRODUCTORY COMMENTS RE: BIOTECH/PHARMA EXTENDED PATENT FAMILIES In complex art areas like biotech/biopharma, patent strategy is about...
Aug 28, 2024


Annual Patent Planning Considerations
It's that time of year again... Annual patent planning for your company/client(s) for next year. Here are some key dates to track as you...
Dec 9, 2023


First Gene Editing FDA Approval - A Day to Celebrate Biotech!
A day to celebrate biotech! 🥳 Congrats to Vertex and CRISPR Therapeutics on FDA approval of CASGEVY • 1st product that uses gene editing...
Dec 9, 2023
Get the latest DHL news and life science patent and investor insights right in your mailbox!
bottom of page